Article

Resurrect Bio has raised $8.1 million in its Series A round, led by Corteva's Catalyst platform, to enhance crop disease resistance. The funding will support product development and team expansion. The company, established in 2021 from The Sainsbury Laboratory, works to restore plants' innate defenses against evolving pathogens by identifying binding interactions between plant immune receptors and pathogen proteins.

Its technology can apply to various crops and multiple threats, aiming for significant resistance improvements. Resurrect Bio is focusing on major crops like soy, corn, and wheat, with plans for 18 disease resistance traits in the next three years.